Luvone et al. Huntington’s Disease Marijuana 2009. Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neuroscience & Therapeutics 15: 65-75.
 Sagredo et al. 2012. Cannabinoids: Novel Medicines for the Treatment of Huntington’s Disease. Recent Patents on CNS Drug Discovery 7: 41-48.
 Gowran et al. 2011. The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neuroscience & Therapeutics 17: 637-644.
 Sagredo et al. 2011. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntingtons disease. Journal of Neuroscience Research 89: 1509-1518.
 Valdeolivas et al. 2012. Sativex-like combination of phytocannabinoids in neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chemical Neuroscience16: 400-406.
 Valdeolivas et al. Effects of a Sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of Huntington’s disease. International Journal of Molecular Sciences 18. [online ahead of print]
 Meisel and Friedman. 2012. Medical marijuana in disease: report of two cases. Medicine and Health, Rhode Island 95: 178-179.
 Sagredo et al. 2012. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Patents on CNS Drug Discovery 7: 41-48.
You must log in to post a comment.